Navigation Links
VivaGel(R) Demonstrates Anti-HIV and Herpes Activity Following Human Administration
Date:8/4/2009

MELBOURNE, Australia, Aug. 4 /PRNewswire-FirstCall/ -- Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) today announced the results of its clinical trial demonstrating that VivaGel(R) retains antiviral activity against human immunodeficiency virus (HIV) and herpes simplex virus (HSV, the virus that causes genital herpes), following vaginal administration in women.

The clinical study was conducted to assess the antiviral activity of VivaGel(R) (SPL7013 Gel) in cervicovaginal fluid samples (CVS) taken from healthy women immediately, then at 1, 3, 12 and 24 hours after separate vaginal doses of the product. These samples were tested for their ability to prevent HIV and genital herpes (HSV-2) infection of susceptible cells in the laboratory.

The study showed that CVS obtained immediately after vaginal administration of VivaGel(R) provided effectively complete inhibition of HIV and HSV infection in vitro.

At 1 and 3 hours following administration of product, the initial high level of inhibition of HIV and HSV was retained in all women tested.

Even at 12 and 24 hours following administration, more than 90% of the initial antiviral activity was retained for both HIV and HSV in more than half of the women enrolled in the study.

This is the first clinical study to demonstrate potent antiviral activity of any microbicide beyond one hour after administration of the product in humans. These data indicate the potential for VivaGel(R) to be used other than immediately prior to sexual intercourse (i.e., as a coitally-dissociated microbicide). However, future testing in clinical efficacy studies is required to confirm this.

"These results are extremely encouraging," said Dr Jackie Fairley, CEO of Starpharma. "They show not only an excellent level of activity, but also a sustainability of effect that exceeded our expectations. The retention of potent activity several hours after administration can only enhance the commercial prospects of VivaGel(R)," Dr Fairley added.

There were no serious adverse events during the study, and as previously announced the data indicate VivaGel(R) was well-tolerated.

The study was conducted in Melbourne at the Centre for Clinical Studies and in collaboration with the Burnet Institute. The study was funded by the U.S. National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Division of AIDS (DAIDS), under Contract No. HHSN266200500042C.*

* The following statement is included in accordance with the requirements of Contract No. HHSN266200500042C:

The content of this announcement does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

    For further information:

    Media
    Buchan Consulting
    Rebecca Wilson
    Tel: +61 3 9866 4722
    Mob: +61 417 382 391
    rwilson@bcg.com.au

    Ellie Papathanasiou
    Tel: +61 2 9237 2800
    epapathanasiou@bcg.com.au

    Starpharma
    www.starpharma.com

    Dr Jackie Fairley
    Chief Executive Officer
    +61 3 8532 2704

    Ben Rogers
    Company Secretary
    +61 3 8532 2702
    ben.rogers@starpharma.com


'/>"/>
SOURCE Starpharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Warning for N-9 - an Opportunity for VivaGel(R)
2. Starpharma and Durex Sign Co-Development Agreement for VivaGel(R)-Coated Condoms
3. CAeHC Demonstrates NHIN-enabled Gateways Among Five California Health Information Exchanges
4. Study demonstrates the anti-inflammatory properties of pine bark extract
5. Study Demonstrates the Anti-Inflammatory Properties of Pine Bark Extract on Inflammatory Mediators COX-2 and 5-LOX
6. Analysis of drug-eluting stents data demonstrates safety, efficacy in on-and-off-label use
7. Clinical Study Demonstrates Superior Bioavailability of Jarrow's Proprietary QH-absorb Formula
8. DaVita Study Demonstrates Clinical Application of Sysmex Reticulocyte Hemoglobin Equivalent (RET-He) Parameter
9. Penn study demonstrates new way to boost immune memory
10. Study Demonstrates Internet Risks for Teen Girls
11. Abbotts XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, Real World Patients in SPIRIT V Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding Christ Through Social Media: ... journal chronicling the writer’s path toward true communion with God. “Finding Christ Through ... is the creation of published author Lea Michelle Johnson, a follower of Christ, ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... collection of inspiring stories about real people of God in congregations across the ... John Miller, a Presbyterian minister ordained in 1964 who has served congregations in ...
(Date:3/23/2017)... ... 2017 , ... A recent report from the National Council on Teacher Quality ... report suggests, based on a review of GPA and SAT/ACT requirements at 221 institutions ... U.S. It argues that this higher bar should be set by states, by the ...
(Date:3/23/2017)... New Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... a new clinic, located at 960 Gruene Road in Building 2. The clinic is ... co-owner Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings ...
(Date:3/23/2017)... ... 23, 2017 , ... The MBI “Hall of Fame” recognizes the contributions of those whose careers ... impact on the careers of all others involved. , On Monday, March 21st, ... MBI’s Hall of Fame. The induction took place during the World of Modular – ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets has ... Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a total ... & Co., Inc., Biogen and Sanofi are involved in the development of ... which one is in Phase III stage, 15 are in Phase II ...
(Date:3/24/2017)... YORK , March 24, 2017 ... and Equipment stocks, which are: Neovasc Inc. (NASDAQ: NVCN), Hologic ... Heart Inc. (NASDAQ: SSH ). These companies are ... its prior gains on Thursday, March 23 rd , 2017, ... afternoon, while shares of health care companies in the S&P ...
(Date:3/24/2017)... surveys with 9,250 insured consumers fielded from February 2015 ... help from their plans in five key areas: 1) ... help closing gaps in care, 3) better digital connections, ... real-time guidance. Meeting these needs is essential to promoting ... A Reason to Stay Engaged in Health ...
Breaking Medicine Technology: